Preclinical News and Research

RSS
FHCRC research represents potential breakthrough in treatment of pancreas cancer

FHCRC research represents potential breakthrough in treatment of pancreas cancer

Heptares exercises exclusive option to license new A2A antagonist for CNS disorders

Heptares exercises exclusive option to license new A2A antagonist for CNS disorders

Researchers identify Wnt pathway as new target for scleroderma therapy

Researchers identify Wnt pathway as new target for scleroderma therapy

Alnylam commences dosing in ALN-TTR02 Phase I clinical trial for TTR-mediated amyloidosis

Alnylam commences dosing in ALN-TTR02 Phase I clinical trial for TTR-mediated amyloidosis

arGEN-X introduces NHance technology to create therapeutic antibodies

arGEN-X introduces NHance technology to create therapeutic antibodies

SK Biopharmaceuticals initiates YKP10811 phase 2 trial in chronic constipation

SK Biopharmaceuticals initiates YKP10811 phase 2 trial in chronic constipation

Merck announces collaboration to create Calibr for early-stage translational research

Merck announces collaboration to create Calibr for early-stage translational research

GenVec 2011 net loss decreases to $7.4 million

GenVec 2011 net loss decreases to $7.4 million

Scientists discover direct biomarker of Chikungunya fever

Scientists discover direct biomarker of Chikungunya fever

AT-1001 shows promise in treating drug addiction

AT-1001 shows promise in treating drug addiction

Publicly available profile of effects of approved and investigational medicines

Publicly available profile of effects of approved and investigational medicines

JAK-STAT inhibitors reverse MS-like disease in mice

JAK-STAT inhibitors reverse MS-like disease in mice

DNDi commences Oxaborole SCYX-7158 Phase I clinical trial for sleeping sickness

DNDi commences Oxaborole SCYX-7158 Phase I clinical trial for sleeping sickness

Allon advances into second phase of work in preclinical PD model

Allon advances into second phase of work in preclinical PD model

InflammaGen Therapeutics initiates Shok-Pak Phase 2 pilot study

InflammaGen Therapeutics initiates Shok-Pak Phase 2 pilot study

FDA clears Aradigm IND for Pulmaquin Phase 3 clinical trial in non-cystic fibrosis BE

FDA clears Aradigm IND for Pulmaquin Phase 3 clinical trial in non-cystic fibrosis BE

ShangPharma fourth quarter net revenues increase 19.0% to $30.5 million

ShangPharma fourth quarter net revenues increase 19.0% to $30.5 million

InflammaGen to initiate Phase 2 study of new drug/delivery platform for shock

InflammaGen to initiate Phase 2 study of new drug/delivery platform for shock

ICON's Nuloy Coronary Stent System receives CE Mark

ICON's Nuloy Coronary Stent System receives CE Mark

Unigene fourth quarter net income increases to $4.4 million

Unigene fourth quarter net income increases to $4.4 million

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.